Bio-Rad Laboratories (BIO) Cash from Investing Activities (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Cash from Investing Activities for 18 consecutive years, with -$93.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 3313.79% year-over-year to -$93.2 million; the TTM figure through Mar 2026 stood at -$285.8 million (down 150.26% YoY), while the FY2025 annual figure was -$189.7 million, down 18.41% from the prior year.
• Cash from Investing Activities slipped to -$93.2 million in Q1 2026 per BIO's latest filing, from -$34.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $72.2 million in Q4 2023 and bottomed at -$916.1 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$95.9 million across 5 years, with a median of -$43.1 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 223.28% — and 2026, when it slumped 3313.79%.
• Bio-Rad Laboratories' Cash from Investing Activities stood at -$58.6 million in 2022, then soared by 223.28% to $72.2 million in 2023, then plunged by 142.25% to -$30.5 million in 2024, then fell by 12.13% to -$34.2 million in 2025, then plunged by 172.51% to -$93.2 million in 2026.
• Business Quant data shows BIO's Cash from Investing Activities at -$93.2 million in Q1 2026, -$34.2 million in Q4 2025, and -$43.0 million in Q3 2025.